Latest news with #Omnipod
Associated Press
23-05-2025
- Business
- Associated Press
Insulet to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025
ACTON, Mass.--(BUSINESS WIRE)--May 23, 2025-- Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced that management will present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 in Miami on Tuesday, June 10, 2025 at 9:20 a.m. (Eastern Time). To listen to the live audio webcast of the presentation, please visit A replay of the webcast will also be available following the event. About Insulet Corporation: Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet's flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit or ©2025 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved. View source version on CONTACT: Investor Relations: June Lazaroff Senior Director, Investor Relations (978) 600-7718 [email protected]: Angela Geryak Wiczek Senior Director, Corporate Communications (978) 932-0611 [email protected] KEYWORD: UNITED STATES NORTH AMERICA FLORIDA MASSACHUSETTS INDUSTRY KEYWORD: DIABETES HEALTH MEDICAL DEVICES SOURCE: Insulet Corporation Copyright Business Wire 2025. PUB: 05/23/2025 06:01 AM/DISC: 05/23/2025 06:01 AM
Business Wire
23-05-2025
- Business
- Business Wire
Insulet to Present at the Goldman Sachs 46 th Annual Global Healthcare Conference 2025
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced that management will present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 in Miami on Tuesday, June 10, 2025 at 9:20 a.m. (Eastern Time). To listen to the live audio webcast of the presentation, please visit A replay of the webcast will also be available following the event. About Insulet Corporation: Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet's flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit or ©2025 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved.
Yahoo
23-05-2025
- Business
- Yahoo
Insulet to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025
ACTON, Mass., May 23, 2025--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 in Miami on Tuesday, June 10, 2025 at 9:20 a.m. (Eastern Time). To listen to the live audio webcast of the presentation, please visit A replay of the webcast will also be available following the event. About Insulet Corporation: Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet's flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit or ©2025 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved. View source version on Contacts Investor Relations: June LazaroffSenior Director, Investor Relations(978) 600-7718jlazaroff@ Media: Angela Geryak WiczekSenior Director, Corporate Communications(978) 932-0611awiczek@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15-05-2025
- Business
- Yahoo
Outlier Money Flows Lift Insulet
Insulet develops, manufactures, and markets the Omnipod Insulin Management System for people with diabetes. This system is worn on the body for approximately three days at a time and allows virtually pain-free automated cannula insertion and blood glucose meter integration. The company's growth is being supported by strategic investments in manufacturing efficiencies and automation, which makes the supply chain leaner and potentially more profitable. PODD's first-quarter fiscal 2025 saw quarterly revenue grow 30% on a year-over-year basis, up to $569 million. Omnipod's total product growth of 29% drove the sales gains, while U.S. Omnipod revenue specifically jumped 26%. Overseas growth of the product was even bigger at 36%. With new customer growth and $1.3 billion on hand, PODD is looking to grow more. It raised full-year revenue growth guidance to a top end of 22% and expects gross margin to rise roughly 71%. It's no wonder PODD shares are up nearly 20% this year – and they could rise more. MoneyFlows data shows how Big Money investors are betting heavily on the forward picture of the stock. Institutional volumes reveal plenty. In the last year, PODD has enjoyed strong investor demand, which we believe to be institutional support. Each green bar signals unusually large volumes in PODD shares. They reflect our proprietary inflow signal, pushing the stock higher: Plenty of health care names are under accumulation right now. But there's a powerful fundamental story happening with Insulet. Institutional support and a healthy fundamental backdrop make this company worth investigating. As you can see, PODD has had strong sales and earnings growth: 3-year sales growth rate (+23.6%) 3-year EPS growth rate (+1,463.2%) Source: FactSet Also, EPS is estimated to ramp higher this year by +24.3%. Now it makes sense why the stock has been powering to new heights. PODD has a track record of strong financial performance. Marrying great fundamentals with our proprietary software has found some big winning stocks over the long term. Insulet has been a top-rated stock at MoneyFlows. That means the stock has unusual buy pressure and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis. It's made the rare Outlier 20 report multiple times in a year. The blue bar below shows when PODD was a top pick…boosted by Big Money inflows: Tracking unusual volumes reveals the power of money flows. This is a trait that most outlier stocks exhibit…the best of the best. Big Money demand drives stocks upward. The PODD rally isn't new at all. Big Money buying in the shares is signaling to take notice. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio. Disclosure: the author holds no position in PODD at the time of publication. If you are a Registered Investment Advisor (RIA) or are a serious investor, take your investing to the next level, learn more about the MoneyFlows process here. This article was originally posted on FX Empire Investors Flock to Royal Gold Netflix Proves Durable Amid Uncertainty Slight Bounce by the Dollar Despite Weaker GDP The Exodus From Safe Havens Duolingo Demand, Earnings Lift Shares Forced Buying That Starts a New Market Phase Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14-05-2025
- Business
- Yahoo
1 Mid-Cap Stock to Target This Week and 2 to Avoid
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo. These dynamics can rattle even the most seasoned professionals, which is why we started StockStory - to help you separate the good companies from the bad. Keeping that in mind, here is one mid-cap stock with huge upside potential and two that could be down big. Market Cap: $11.21 billion Formerly Crown Cork & Seal, Crown Holdings (NYSE:CCK) produces packaging products for consumer marketing companies, including food, beverage, household, and industrial products. Why Do We Think CCK Will Underperform? Constant currency revenue growth has disappointed over the past two years and shows demand was soft Anticipated sales growth of 2% for the next year implies demand will be shaky Gross margin of 20.3% reflects its high production costs Crown Holdings is trading at $97.77 per share, or 14x forward P/E. If you're considering CCK for your portfolio, see our FREE research report to learn more. Market Cap: $15.99 billion With a history dating back to 1931 and products used in over 100 countries, Baxter International (NYSE:BAX) provides essential healthcare products including dialysis therapies, IV solutions, infusion systems, surgical products, and patient monitoring technologies to hospitals and clinics worldwide. Why Do We Steer Clear of BAX? Customers postponed purchases of its products and services this cycle as its revenue declined by 10.3% annually over the last two years Weak constant currency growth over the past two years indicates challenges in maintaining its market share Earnings per share decreased by more than its revenue over the last five years, showing each sale was less profitable At $31.10 per share, Baxter trades at 12.4x forward P/E. Dive into our free research report to see why there are better opportunities than BAX. Market Cap: $22.13 billion Revolutionizing diabetes care with its tubeless "Pod" technology, Insulet (NASDAQ:PODD) develops and manufactures innovative insulin delivery systems for people with diabetes, primarily through its Omnipod product line. Why Are We Bullish on PODD? Average constant currency growth of 26.6% over the past two years demonstrates its ability to grow internationally despite currency fluctuations Incremental sales significantly boosted profitability as its annual earnings per share growth of 114% over the last five years outstripped its revenue performance Free cash flow margin increased by 21.9 percentage points over the last five years, giving the company more capital to invest or return to shareholders Insulet's stock price of $313.30 implies a valuation ratio of 71.1x forward P/E. Is now the time to initiate a position? Find out in our full research report, it's free. Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free.
